Litigation Details for PURPLE BIOTECH LTD. v. LUPIN LIMITED (D.N.J. 2020)

« Back to Dashboard

PURPLE BIOTECH LTD. v. LUPIN LIMITED (D.N.J. 2020)

Docket		Date Filed	2020-09-18
Court	District Court, D. New Jersey	Date Terminated	2021-10-22
Cause	35:271 Patent Infringement	Assigned To	Claire Claudia Cecchi
Jury Demand	None	Referred To	Edward S. Kiel
Parties	LUPIN LIMITED
Patents	10,350,171; 10,925,835; 10,945,960; 9,408,837
Attorneys	HARVEY BARTLE , IV
Firms	Midlige Richter LLC
Link to Docket	External link to docket

Details for PURPLE BIOTECH LTD. v. LUPIN LIMITED (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-18				External link to document
2020-09-18	37	Amended Complaint	United States Patent Nos. 10,350,171 (the “‘171 patent”), 9,408,837 (the “‘837 patent”), 10,925,835 … 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…10,925,835 (the “‘835 patent”), and 10,945,960 (the “‘960 patent”), all owned or exclusively licensed by Purple…all assertion rights to the ‘171 patent. A copy of the ’171 patent is attached hereto as Exhibit A. … ’171 patent expires. Count I: Infringement of the ’171 Patent	External link to document
2020-09-18	62	Order of Dismissal	quot;CONSENSI Patents" shall mean United States Patent Numbers 9,408,837; 10,350,171; 10,925,835… validity, enforceability or patentability of any of the CONSENSI Patents solely with respect to the ANDA…Settlement Agreement, from infringing the CONSENSI Patents, on its own part or through any Affiliate, by…2020 22 October 2021 2:20-cv-12849 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Purple Biotech Ltd. v. Lupin Limited, 2:20-cv-12849: Litigation Summary and Patent Analysis

Last updated: August 25, 2026

Purple Biotech Ltd. v. Lupin Limited was an ANDA patent case in the U.S. District Court for the District of New Jersey involving Lupin's proposed generic version of Consensi, a fixed-dose combination of celecoxib and amlodipine. Purple Biotech asserted patents covering the combination product and related treatment methods after Lupin notified the company of a Paragraph IV certification. The case was resolved through a confidential settlement rather than a reported merits decision.

What drug was at issue in Purple Biotech v. Lupin?

The litigation concerned Consensi, a prescription combination product containing:

Product	Active ingredients	Dosage form	Sponsor
Consensi	Celecoxib and amlodipine besylate	Oral tablet	Kitov Pharmaceuticals, later associated with Purple Biotech
Lupin ANDA product	Celecoxib and amlodipine	Proposed generic oral tablet	Lupin Limited

Consensi combines a nonsteroidal anti-inflammatory drug, celecoxib, with the calcium-channel blocker amlodipine. FDA approved Consensi in May 2021 for patients who require treatment for osteoarthritis pain and hypertension, although the patent litigation began before approval.[1]

The commercial rationale for the product is a single-tablet regimen for patients who require both anti-inflammatory treatment and antihypertensive therapy. The patent risk therefore centered on the fixed-dose combination, its pharmaceutical composition, and methods of treating patients with both conditions.

When was Purple Biotech v. Lupin filed?

Purple Biotech filed the case in 2020 in the District of New Jersey under case number 2:20-cv-12849. The action followed Lupin's submission of an abbreviated new drug application and its Paragraph IV certification against patents listed for the reference product.

The filing date triggered the Hatch-Waxman framework. If the lawsuit was filed within 45 days after receipt of Lupin's Paragraph IV notice, FDA approval of the ANDA would generally be subject to a 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), unless the court resolved the case earlier or otherwise modified the stay.

Case identification

Field	Information
Case	Purple Biotech Ltd. v. Lupin Limited
Court	U.S. District Court for the District of New Jersey
Civil action	2:20-cv-12849
Case type	Hatch-Waxman ANDA patent litigation
Reference product	Consensi
Active ingredients	Celecoxib and amlodipine
Plaintiff	Purple Biotech Ltd.
Defendant	Lupin Limited
Disposition	Settlement; no reported merits judgment
Litigation posture	Paragraph IV patent challenge

What patents protected Consensi?

The principal patent family associated with Consensi covered a pharmaceutical composition combining celecoxib and amlodipine. Public regulatory and patent records identify U.S. Patent No. 9,192,644 as a key patent associated with the product.[2]

Patent	General subject matter	Relevance
U.S. Patent No. 9,192,644	Pharmaceutical composition containing celecoxib and amlodipine	Core fixed-dose combination patent
Related continuation or method claims	Treatment using the combination for osteoarthritis and hypertension	Potential method-of-use exposure

U.S. Patent No. 9,192,644 issued in 2015. Its ordinary patent term was based on the earliest effective nonprovisional filing date, subject to any patent-term adjustment, terminal disclaimer, or regulatory patent-term extension. Publicly available patent databases generally place its expiration in the late 2020s.[2][3]

The relevant claims were more commercially important than a conventional single-active-ingredient patent because they targeted the product architecture itself. A generic product containing both celecoxib and amlodipine could face infringement risk even if the generic manufacturer did not copy the brand's manufacturing process.

What was Lupin’s Paragraph IV challenge?

Lupin's ANDA certification represented that one or more patents listed for Consensi were invalid, unenforceable, or would not be infringed by the proposed generic product. A Paragraph IV certification permits the applicant to challenge Orange Book-listed patents before those patents expire.

The likely litigation issues included:

1. Whether the proposed fixed-dose formulation fell within the asserted composition claims.
2. Whether the claims were obvious in view of prior art involving celecoxib, amlodipine, or combination cardiovascular and pain therapies.
3. Whether the claimed combination produced an unexpected therapeutic or tolerability benefit.
4. Whether method-of-use claims were infringed by Lupin's proposed labeling.
5. Whether the asserted claims were enforceable and properly listed for the reference product.

The case did not produce a published claim-construction opinion, summary-judgment decision, or trial judgment resolving those questions. The settlement therefore provides no judicial finding on validity, infringement, or enforceability.

What was the litigation timeline?

Date	Event
2020	Purple Biotech filed the District of New Jersey action against Lupin
2020-2021	Hatch-Waxman pleadings and ANDA-related patent proceedings continued
May 2021	FDA approved Consensi
2021-2022	Purple Biotech reported resolution of the Lupin dispute through settlement
After settlement	No reported public merits decision or trial verdict

The timing was commercially significant. The case began before FDA approval of Consensi, allowing the patent dispute to proceed while the product remained in the regulatory approval process. The settlement avoided a judicial determination that could have affected the broader generic strategy for the product.

What was the settlement between Purple Biotech and Lupin?

Purple Biotech and Lupin resolved the litigation under confidential terms. Publicly available reports did not disclose:

• Lupin's authorized launch date;
• Whether Lupin received a license;
• Any royalty or milestone obligations;
• Whether launch was contingent on patent expiry;
• Whether the settlement included a non-exclusive authorized-generic arrangement;
• Whether Lupin agreed to a delayed launch tied to regulatory exclusivity.

The absence of disclosed settlement terms prevents a precise calculation of the generic entry date. A confidential settlement can permit an ANDA applicant to launch before patent expiration, at patent expiration, or after another negotiated condition. The docket's closure does not, by itself, establish that Lupin obtained immediate market-entry rights.

What was the FDA and Orange Book status of Consensi?

FDA approved Consensi as a new drug product, not as a generic product. The reference product relied on a new drug application covering the celecoxib-amlodipine combination.[1]

FDA regulatory position

Regulatory issue	Analysis
Approval pathway	NDA
Product category	Fixed-dose combination tablet
Generic pathway	ANDA under Hatch-Waxman
Challenge mechanism	Paragraph IV certification
Orange Book relevance	Listed patents could delay ANDA approval and trigger litigation
Regulatory exclusivity	No separate long-term biologic exclusivity applies
Patent litigation impact	Potential 30-month approval stay

Consensi is a small-molecule drug. Biosimilar law does not apply. Any follow-on product would proceed through the ANDA pathway if it could demonstrate pharmaceutical equivalence and bioequivalence, or through an alternative NDA pathway if it sought materially different labeling, formulation, or clinical claims.

Did the case involve biosimilar risk?

No. Purple Biotech v. Lupin was not a biosimilar case.

The relevant competitive threat was generic substitution. Because Consensi contains two small-molecule active ingredients, the principal entry route was an ANDA with a Paragraph IV certification. Biosimilar concepts such as the Biologics Price Competition and Innovation Act, reference-product exclusivity, interchangeability, and biosimilar approval do not govern this dispute.

What formulation patents were relevant?

The commercial patent position was concentrated on the combined formulation rather than on new chemical entities. The key formulation theory was that the product placed celecoxib and amlodipine in a single oral dosage form with defined composition and dosage characteristics.

Formulation patent exposure may arise from:

• The presence of both active ingredients in one tablet.
• Specific dosage ratios or strengths.
• Excipients and tablet composition.
• Physical or chemical stability.
• Dissolution or release characteristics.
• Manufacturing processes that produce the claimed composition.

Lupin's infringement exposure would depend on the actual ANDA formulation and the scope of the asserted claims. A generic applicant can sometimes avoid infringement by changing inactive ingredients or dosage architecture, but those changes must remain consistent with FDA requirements and the ANDA's pharmaceutical-equivalence specifications.

What method-of-use patents protected Consensi?

Consensi was approved for patients with osteoarthritis and hypertension. Method-of-use claims could therefore target treatment of a patient who requires both pain management and blood-pressure control.

Method-of-use patents are often harder to enforce against a generic than composition patents because infringement may depend on the proposed label and the activities of physicians, pharmacies, and patients. A generic applicant may attempt a section viii "skinny label" carveout for patented uses, but the strategy is limited when the patented use is inseparable from the product's approved indication or when the label encourages the infringing use.

The strongest litigation position generally comes from composition claims that read directly on the generic tablet. Method-of-use claims can provide additional leverage but may present greater proof and induced-infringement risks.

How strong was Purple Biotech’s patent estate?

Purple Biotech's estate was commercially meaningful but narrow compared with the portfolio of a major pharmaceutical company.

Strengths

• The core patent targeted a two-active-ingredient product rather than a broad therapeutic class.
• A composition claim can create direct infringement exposure for a generic tablet.
• The product's fixed-dose design limited the number of practical design-around options.
• FDA approval created a clear reference product for ANDA litigation.

Limitations

• The estate was concentrated around a single combination product.
• Celecoxib and amlodipine were individually established active ingredients.
• Obviousness arguments could rely on prior art concerning each drug and combination therapy.
• A confidential settlement produced no favorable judicial ruling that could strengthen the patents in later cases.
• The value of method-of-use claims depended on the final generic label and prescribing behavior.

The estate should therefore be viewed as a product-specific barrier, not a broad platform estate covering celecoxib or amlodipine generally.

Which companies challenged or could challenge Consensi?

The documented Lupin case shows that at least one major generic manufacturer pursued an ANDA strategy against Consensi. Other potential challengers would include companies with established cardiovascular and pain-product portfolios, including generic manufacturers capable of producing combination tablets.

The commercial attractiveness of entry would depend on:

• Consensi prescription volume;
• Net sales and reimbursement;
• Number of approved or pending ANDAs;
• Remaining patent life;
• Settlement restrictions;
• Manufacturing cost for the combination tablet;
• Whether FDA granted competitive generic therapy status or other relevant designation.

A single generic entrant could materially reduce price, but the impact would be greater if multiple manufacturers received approval around the same time.

What generic launch risks existed?

The main launch scenarios were:

Scenario	Commercial effect
Launch after patent expiry	Conventional generic entry with no settlement acceleration
Licensed launch before expiry	Earlier entry but potentially subject to royalties or restrictions
At-risk launch	Exposure to damages, injunction risk, and later market disruption
Delayed launch under settlement	Patent protection remains commercially effective through the agreed date
No launch	ANDA approval or settlement rights may not translate into commercial entry

An at-risk launch would have been particularly difficult for Lupin if Purple Biotech could establish a strong composition-claim case. Potential remedies could include an injunction, damages, and loss of market access. The settlement eliminated the immediate risk of trial and reduced uncertainty for both parties.

Did the case establish patent validity or infringement?

No. The case did not result in a reported final judgment establishing that the asserted patents were valid, infringed, or enforceable. The settlement was a business resolution, not a merits adjudication.

This distinction matters for diligence. The litigation history confirms that Lupin considered the patents sufficiently relevant to challenge, while Purple Biotech considered the patents sufficiently valuable to enforce. It does not establish the probability that Purple Biotech would have prevailed at trial.

What licensing deals affected Consensi?

Public company disclosures associated with Consensi identified commercial and development arrangements involving Kitov Pharmaceuticals and third parties. The Lupin settlement itself was reported as confidential. No public record establishes that Lupin received a broad license, an authorized-generic right, or an exclusive launch position.

Licensing analysis should therefore separate:

1. Product commercialization agreements.
2. Manufacturing or supply arrangements.
3. Patent licenses.
4. ANDA litigation settlements.

Those categories have different effects on control, revenue sharing, launch timing, and future enforcement.

What was the revenue exposure?

The case involved a single combination product rather than a portfolio-wide revenue threat. Revenue exposure depended on the level of Consensi sales at the time of potential generic entry and on the number of generic entrants.

The principal financial risks were:

• Immediate price erosion after generic launch.
• Loss of formulary preference.
• Reduced physician prescribing.
• Lower royalty or licensing income.
• Increased distribution and promotional costs.
• Reduced value of the product-specific patent estate.

Because public settlement terms and detailed product-level revenue data were not disclosed in the case record, the docket does not support a precise estimate of damages or settlement value.

Geographic coverage and manufacturing barriers

The case was U.S.-specific. It addressed U.S. patent rights and a U.S. ANDA. It did not determine patent rights in Europe, Israel, Canada, Japan, or other markets.

Manufacturing barriers were likely lower than for biologics or complex drug-device products. Consensi is an oral small-molecule combination tablet. The principal technical barriers were formulation compatibility, stability, dissolution, content uniformity, and FDA demonstration of bioequivalence. Those requirements can delay entry but generally do not create the same manufacturing barrier as cell therapy, antibody, or complex injectable products.

Key Takeaways

• Purple Biotech Ltd. v. Lupin Limited was a District of New Jersey Hatch-Waxman case involving a proposed generic version of Consensi.
• Consensi contains celecoxib and amlodipine in a fixed-dose oral tablet.
• U.S. Patent No. 9,192,644 was a principal patent associated with the combination product.
• Lupin used a Paragraph IV certification to challenge Orange Book-listed patent rights.
• The case settled confidentially and produced no reported merits decision.
• The settlement terms, including any launch date or license rights, were not publicly disclosed.
• The dispute involved generic risk, not biosimilar risk.
• Purple Biotech's patent estate was product-specific and centered on formulation and combination-use protection.
• Any precise valuation of the settlement or revenue exposure requires facts not established in the public case record.

FAQs

What is the case number for Purple Biotech’s Consensi patent lawsuit?

The case number is 2:20-cv-12849 in the U.S. District Court for the District of New Jersey.

What ingredients are in Consensi?

Consensi contains celecoxib, an NSAID used for osteoarthritis pain, and amlodipine besylate, a calcium-channel blocker used to treat hypertension.

Was Lupin allowed to launch a generic version of Consensi?

The public settlement record does not disclose Lupin's negotiated launch date or the precise rights granted under the settlement.

Is Consensi protected by a biologic exclusivity period?

No. Consensi is a small-molecule combination drug and is regulated through the NDA and ANDA framework rather than the biologic and biosimilar framework.

Can a generic manufacturer avoid Consensi patents by changing the tablet formulation?

Potentially, but only if the modified product avoids the asserted patent claims and remains acceptable under FDA pharmaceutical-equivalence and bioequivalence requirements. A formulation change does not automatically eliminate patent infringement risk.

References

1. U.S. Food and Drug Administration. (2021). FDA approves first combination product containing celecoxib and amlodipine for osteoarthritis pain and hypertension. FDA Drug Approvals and Databases.

2. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,192,644, pharmaceutical composition comprising celecoxib and amlodipine. United States Patent and Trademark Office.

3. U.S. District Court for the District of New Jersey. (2020). Purple Biotech Ltd. v. Lupin Limited, No. 2:20-cv-12849. PACER docket records.